ClinicalTrials.gg
CompletedNCT00116116Updated Apr 26, 2011

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

A Phase 4 interventional study of efavirenz, stavudine extended release, lamivudine in HIV Infections and AIDS, sponsored by Bristol-Myers Squibb. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-26.

Primary conditionAcquired Immunodeficiency SyndromeRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acquired Immunodeficiency Syndrome
Why
  1. The study's listed conditions name Acquired Immunodeficiency Syndrome, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing efavirenz in Acquired Immunodeficiency Syndrome — 1 open to participants now, 1 under way, none of them phase 3. efavirenz · Acquired Immunodeficiency Syndrome.

Enrollment
13th of 20
70 · median 154
Started
2002
with 1 other
Phase 4
8 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
4 of 20
Bristol-Myers Squibb

Among the 20 studies testing efavirenz in Acquired Immunodeficiency Syndrome, this one is the 13th largest by enrollment, is one of 2 that started in 2002, is one of 8 in phase 4, and was the 2nd registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

1 of the 20 studies testing efavirenz in Acquired Immunodeficiency Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About efavirenz

efavirenz: first FDA approval 1998 (SUSTIVA), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efavirenz in Acquired Immunodeficiency Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether a therapy with an all once daily regimen of stavudine extended release (d4T XR), lamivudine (3TC), and efavirenz (EFV) leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability.

03

Conditions studied

  • HIV Infections
  • AIDS

Browse trials for

Keywords

  • HIV/AIDS
04

In context

Acquired Immunodeficiency Syndrome Reclassified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 70 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years of age or older infected with and weigh at least 40 kg.
  • Plasma HIV RNA viral load of 1000 copies/mL or greater and of 100 cells/mL or greater.
  • Be willing to use two forms of throughout study.
  • No previous exposure to antiretroviral (ARV) drugs

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Physical or psychiatric disability
  • Proven or suspected acute hepatitis within 30 days prior to study entry
  • Active AIDS-defining opportunistic infection or disease
  • History of acute or chronic pancreatitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants

Interventions

07

What researchers measure

Primary outcomes

  1. Estimate efficacy of d4T-XR/3TC/EFV given QD determined by

  2. proportion of patients with plasma HIV RNA < 400 copies/mL after 48 weeks

Secondary outcomes

  1. Evaluate proportion of patients with plasma HIV RNA < 400 copies/mL at Weeks 24, 48, 72, and 96

  2. Evaluate the proportion of patients with plasma HIV RNA < 50 copies/mL at Weeks 24, 48, 72, and 96

  3. Determine viral suppression of plasma HIV RNA change in baseline at week 48

  4. Determine proportion of patients whose HIV viral load doesn't drop to undetectable level within 24 weeks of therapy initiation

  5. Evaluate time to undetectable plasma HIV RNA

  6. Evaluate proportion of patients demonstrating virologic breakthrough

  7. Evaluate proportion of patients demonstrating virologic failure

  8. Evaluate time to virologic breakthrough and virologic failure

  9. Measure magnitude and durability of changes in CD4 cell counts

  10. Evaluate patient adherence with QD regimen using pill counts and AMAF

  11. Determine pattern and emergence of HIV genotype resistance mutations in subjects experiencing virologic failure

  12. Explore QoL changes using MOS-HIV health survey

  13. Evaluate safety and tolerability of QD regimen

08

Study locations

10 sites
  • Local Institution
    Bakersfield, California, United States
  • Local Institution
    San Francisco, California, United States
  • Local Institution
    Washington, District of Columbia, United States
  • Local Institution
    Ft. Lauderdale, Florida, United States
  • Local Institution
    Jacksonville, Florida, United States
  • Local Institution
    Miami, Florida, United States
  • Local Institution
    New York, New York, United States
  • Local Institution
    Greenville, North Carolina, United States
  • Local Institution
    Oklahoma City, Oklahoma, United States
  • Local Institution
    Dallas, Texas, United States
09

References and documents

Publications

  • Jayaweera D, Dejesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naive HIV-1-infected patients over 96 weeks. HIV Clin Trials. 2009 Nov-Dec;10(6):375-84. doi: 10.1310/hct1006-375. PubMed 20133268 ↗
  • Nunes EP, Santini de Oliveira M, Mercon M, Zajdenverg R, Faulhaber JC, Pilotto JH, Ribeiro JE, Norton M, Schechter M. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials. 2009 Nov-Dec;10(6):368-74. doi: 10.1310/hct1006-368. PubMed 20133267 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002, a primary completion of Jun 2005 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2005
First posted
Jun 28, 2005
Start
Mar 2002
Primary completionActual
Jun 2005
CompletionActual
Jun 2005
Results delay requested
Jan 27, 2010
Last update
Apr 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00116116
First posted
Jun 28, 2005
Start date
Mar 2002
Primary completion
Jun 2005
Completion
Jun 2005
Last update
Apr 26, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efavirenz · Stavudine · Lamivudine

Start the discussion